Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

Zinman, Bernard; Gerich, John; B Buse, John; Lewin, Andrew; Schwartz, Sherwyn; Raskin, Philip; M Hale, Paula; Zdravkovic, Milan; Blonde, Lawrence; Study Investigators, LEAD-4

doi:10.2337/dc08-2124

Public

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

Shared by NobleBlocks on Jul 1, 2009 • 12:00 AM UTC

Authors:

Bernard Zinman

John Gerich

John B Buse

Abstract

OBJECTIVE: To determine the efficacy and safety of liraglutide (a glucagon-like peptide-1 receptor agonist) when added to metformin and rosiglitazone in type 2 diabetes. RESEARCH DESIGN AND METHODS: This 26-week, double-blind, placebo-controlled, parallel-group trial randomized 533 subjects (1:1:1) ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!